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Introduction
Aggressive and accelerated atherosclerosis is a major
problem in systemic lupus erythematosus (SLE) and is one
of its major causes of death, an observation first made more
than 20 years ago by Urowitz [1]. Coronary artery disease
develops in 6–9% of SLE patients and accounts for up to
36.4% of deaths in SLE. High rates of atherosclerotic vas-
cular disease (ASVD) are particularly striking in young
women with SLE, normally at low risk. The incidence of
myocardial infarction in women with SLE aged 35–44 years
is 50-fold greater than in women of similar ages from a pop-
ulation-based sample [2]. Non-invasive methods of demon-
strating atherosclerotic disease, such as carotid duplex
ultrasound, electron-beam computed tomography, and thal-
lium perfusion scanning, and one autopsy study, suggest
that symptomatic disease might be the tip of the iceberg.
The true incidence could be as high as 74% [3–10].
The pathophysiology of SLE-associated atherosclerosis is
unknown, but the emerging picture is that many of the
same risk factors as those observed in normal individuals
are also involved. This has motivated authorities in both
rheumatology and preventive cardiology to advocate more
aggressive risk factor assessment and management of risk
factors [11–17]. There are theoretical and practical barri-
ers to improving atherosclerosis-related outcomes in SLE
suggesting that this approach will be challenging, and the
potential benefit is yet unknown.
First, when risk factors are examined quantitatively, SLE
and/or its treatment (most probably with corticosteroids) are
the most important risk factors. Indeed, data from Esdaile and
colleagues suggest that even after adjusting for ‘normal risk’,
SLE and/or its treatment increases the risk of coronary artery
disease 5–10-fold [18]. This suggests that even if physicians
were perfectly virtuous, sought out risk factors aggressively
and followed guidelines scrupulously; and patients were toler-
ant, compliant, and responsive to lipid-lowering strategies and
blood pressure control, for example, there would still be
excess mortality and morbidity from ASVD.
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Abstract
Accelerated atherosclerotic vascular disease (ASVD) is a major cause of death in systemic lupus
erythematosus (SLE). Although many authorities are calling for aggressive assessment and
management of cardiac risk factors in patients with SLE, both theoretical and practical barriers to this
approach exist. It seems that SLE and/or its treatment are themselves strong risk factors for the
development of ASVD and it is unclear how much this risk can be decreased by the control of
traditional risk factors. Studies from several centers have shown that suboptimal risk factor
management and barriers to acceptance of these measures must also be studied further.
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Second, studies from Toronto and Baltimore show that
risk factor identification and, by implication, treatment fall
short of what one would predict from the importance of
the problem [13,19]. We know that patients with chronic
diseases such as SLE, rheumatoid arthritis, and diabetes
are less likely to receive the highest quality of preventive
health care, perhaps because more urgent problems must
be dealt with first, or perhaps because of patients’ and
physicians’ exhaustion in dealing with chronic health prob-
lems. Patients can find it difficult to change their lifestyles
and take additional medications on top of complicated
regimens or little reinforcement from their providers. In
recruiting patients with SLE and hyperlipidemia for a statin
dosing study, our experience has been that the patients
who are the most willing to participate are relatively young
and healthy, with very mild SLE, and few other health
problems or medications. Among those patients with more
long-standing and severe SLE, reasons for non-participa-
tion have included, ‘I’m flaring and don’t want to take
another medication that might make me sick’, ‘I’m trying to
get healthy’, and ‘I’m too sick and have too many doctor’s
appointments already’.
Conclusion
HL Mencken once quipped, ‘For every complex problem,
there is a solution which is simple, neat and wrong’. We
have known for over 20 years of the late complications of
SLE. The received wisdom that we need only try harder to
implement the known effective preventive strategies for
normal individuals is simple and neat, but might be wrong
or incomplete.
Several questions remain unanswered in our search for a
successful approach to the prevention of ASVD in SLE. The
etiologic factors responsible for vascular injury in SLE need
to be understood more precisely. For example, do short-
term hypertension, hyperlipidemia, and immune complex
generation of an SLE flare do as much or more damage to
the endothelium as does lower-grade inflammation or expo-
sure to traditional risk factors for many years? In addition, a
better understanding of patient social and cultural factors
will be essential to achieving acceptance of lifestyle
changes and medications. Progress will only be made as
basic science brings an understanding of the mechanisms
of accelerated atherosclerosis in SLE and as clinical studies
address both the efficacy and the effectiveness of existing
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